Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 8Recruiting 6Unknown 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 487Gastrointestinal 72Breast 64Genitourinary 50Head & Neck 33Gynecologic 28Dermatologic 27CNS 27Sarcoma 19Other solid neoplasm 11Lymphoid 7Endocrine 5Plasma cell 4Other hematologic neoplasm 4Classical hematology 3Myeloid 2Other neoplasm 1Other 1NET 1

Conditions

Neuroendocrine Tumors 46Neoplasms 8Carcinoid Tumor 7Neoplasm Metastasis 5Gastro-enteropancreatic neuroendocrine tumor 5Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Serotonin Syndrome 2Sarcoma 2Pheochromocytoma 2Paraganglioma 2Neuroblastoma 2Neoplasms by Site 2Digestive System Neoplasms 2Digestive System Diseases 2Cholangiocarcinoma 2Carcinoma, Islet Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Adrenal Gland Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1

Interventions

Oxaliplatin 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lung Neoplasms × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡